Nippon Chemiphar: Interim Report

EDINETJun 18 09:36 · Announcements

Nippon Chemiphar: Securities Report – Fiscal Year 94 (April 1, 2025 – March 31, 2026)

EDINETJun 15 10:58 · Announcements

Nippon Chemiphar Co Sees FY Net Y60.00M

Dow JonesJun 10 16:40

Nippon Chemiphar Co FY Net Y198.00M Vs Net Y294.00M

Dow JonesJun 10 16:40

Nippon Chemiphar: Notice Regarding Dividends on Retained Earnings

JPXMay 21 14:30 · Announcements

Terumo reported an 11.8% increase in operating profit to 176.3 billion yen for the fiscal year ending March 26, and forecasts a 27.3% increase to 224.5 billion yen for the fiscal year ending March 27.

Terumo <4543> announced its consolidated financial results for the fiscal year ending March 2026, reporting a 9.2% year-on-year increase in revenue to 1.131877 trillion yen and an 11.8% rise in operating income to 176.32 billion yen. In the cardiovascular company segment, overseas operations grew across all businesses, particularly driven by the interventional systems business. Additionally, in the Blood and Cell Technologies Company segment, global expansion of the plasma innovation business accelerated in North America, contributing to overall growth.

Fisco JapanMay 18 05:21